305 related articles for article (PubMed ID: 14687799)
1. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
2. The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells.
David A; Kopecková P; Kopecek J; Rubinstein A
Pharm Res; 2002 Aug; 19(8):1114-22. PubMed ID: 12240936
[TBL] [Abstract][Full Text] [Related]
3. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Omelyanenko V; Kopecková P; Gentry C; Kopecek J
J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
[TBL] [Abstract][Full Text] [Related]
4. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.
Kopansky E; Shamay Y; David A
J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249
[TBL] [Abstract][Full Text] [Related]
5. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes.
Omelyanenko V; Kopecková P; Prakash RK; Ebert CD; Kopecek J
Pharm Res; 1999 Jul; 16(7):1010-9. PubMed ID: 10450924
[TBL] [Abstract][Full Text] [Related]
6. Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes.
Tang A; Kopeiková P; Kopeckevá J
Pharm Res; 2003 Mar; 20(3):360-7. PubMed ID: 12669954
[TBL] [Abstract][Full Text] [Related]
7. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
8. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.
Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R
J Drug Target; 1996; 3(5):385-90. PubMed ID: 8866657
[TBL] [Abstract][Full Text] [Related]
9. A novel α
Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z
J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244
[TBL] [Abstract][Full Text] [Related]
10. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
13. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
14. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
15. Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells.
David A; Kopecková P; Rubinstein A; Kopecek J
Bioconjug Chem; 2001; 12(6):890-9. PubMed ID: 11716678
[TBL] [Abstract][Full Text] [Related]
16. Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.
Xiang Y; Shan W; Huang Y
Int J Pharm; 2018 Nov; 551(1-2):14-22. PubMed ID: 30205127
[TBL] [Abstract][Full Text] [Related]
17. Self-association properties of HPMA copolymers containing an amphipathic heptapeptide.
Ding H; Kopecková P; Kopecek J
J Drug Target; 2007; 15(7-8):465-74. PubMed ID: 17671893
[TBL] [Abstract][Full Text] [Related]
18. HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
Sirova M; Kabesova M; Kovar L; Etrych T; Strohalm J; Ulbrich K; Rihova B
Curr Med Chem; 2013; 20(38):4815-26. PubMed ID: 24083609
[TBL] [Abstract][Full Text] [Related]
19. G3-C12 Peptide Reverses Galectin-3 from Foe to Friend for Active Targeting Cancer Treatment.
Sun W; Li L; Yang Q; Shan W; Zhang Z; Huang Y
Mol Pharm; 2015 Nov; 12(11):4124-36. PubMed ID: 26393405
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells.
Kovar L; Etrych T; Kabesova M; Subr V; Vetvicka D; Hovorka O; Strohalm J; Sklenar J; Chytil P; Ulbrich K; Rihova B
Tumour Biol; 2010 Aug; 31(4):233-42. PubMed ID: 20556593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]